Article Text

other Versions

PDF
Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis
  1. Alexander Konnopka (alexander.konnopka{at}medizin.uni-leipzig.de)
  1. University of Leipzig, Germany
    1. Karsten Conrad (k_conrad{at}mail.zih.tu-dresden.de)
    1. Technical University Dresden, Germany
      1. Christoph Baerwald (christoph.baerwald{at}medizin.uni-leipzig.de)
      1. University of Leipzig, Germany
        1. Hans-Helmut Koenig (hans-helmut.koenig{at}medizin.uni-leipzig.de)
        1. University of Leipzig, Germany

          Abstract

          Aims: This study aims to estimate the incremental cost-effectiveness ratio (ICER) of antibodies against cyclic citrullinated peptides (aCCP) in the early diagnosis of rheumatoid arthritis (RA).

          Methods: A Markov model was utilised to model 10 year progression of RA in patients first diagnosed as undifferentiated arthritis (UA) and to estimate the incremental costs and quality adjusted life years (QALYs) of using aCCP additionally to ACR criteria. Impact of later diagnosis and therapy due to non-use of aCCP was modelled as increased HAQ-progression. Utilities were assigned to HAQ-states for calculating QALYs. Uncertainty was analysed using univariate and probabilistic sensitivity analyses (Monte-Carlo-Simulation).

          Results: Baseline ICER was 930 Euro/QALY. Univariate sensitivity analyses identified the impact of later diagnosis on HAQ progression as major source of uncertainty resulting in an ICER range from “dominance” to 153,092 Euro/QALY, compared to a maximum ICER of 4,870 Euro/QALY for other variables. Monte Carlo simulation resulted in a 95%-uncertainty interval from –3,537 Euro/QALY (dominance) to 5,429 Euro/QALY; when indirect costs were considered, Monte Carlo simulation resulted in a 95%-uncertainty interval from –78,115 Euro/QALY (dominance) to –23,444 Euro/QALY (dominance).

          Conclusions: Using aCCP in the diagnosis of RA in patients with UA is likely to be a cost-effective strategy compared to ACR-criteria alone. Considering indirect costs, aCCP seems to be a cost saver. There is a clear need for more research relating the effects of an early or early diagnosis and therapy on the long-term course and resulting functional impairment of RA as measured by the HAQ.

          • aCCP
          • cost-effectiveness
          • rheumatoid arthritis
          • undifferentiated arthritis

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.